PARIS, Dec 7 (Reuters) - Sanofi shares rose by around 8% in early Paris stockmarket trading on Wednesday after the company avoided thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
GSK Plc, Pfizer Inc, and unlisted Boehringer Ingelheim were also among the companies benefitting from the court ruling. (Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)